Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Comparison of Flurpiridaz (18F) Manufacturing Processes (HPLC vs SPE)
NCT04594941Phase 2Completed
- Sponsor
- GE HealthCare
- Start
- Jan 2022
- Primary completion
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of Flurpiridaz F 18 in coronary artery disease (CAD), sponsored by GE HealthCare. Started Jan 2022; status: completed.
02
Drugs
Flurpiridaz F 18
03
Conditions
coronary artery disease (CAD)
Beyond the preview
Go deeper on NCT04594941.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04594941.